However, this idea has been questioned in recent studies: it has been shown that there is no positive correlation between CD8+ T cell numbers and neoantigen load in breast and prostate cancers and that the characteristics of high tumor mutational load is not predictive of the efficacy of ICT in patients with breast and prostate cancer. This evidence concerns the gene CD8A and Familial prostate cancer.